A Multicenter Retrospective Study on the Safety and Efficacy of the Surpass Evolve Flow Diverter System for the Treatment of Intracranial Aneurysms

Objective: To evaluate the safety and efficacy of the Surpass Evolve flow diverter system for the treatment of intracranial aneurysms across three medical centers. Methods: A retrospective review was conducted on patients with intracranial aneurysms treated with the Surpass Evolve FDS between March 2023 and May 2024 at three participating centers. Primary outcome measures included the rate of complete aneurysm occlusion (Raymond-Roy class 1) and the incidence of periprocedural major stroke and mortality. Secondary outcomes encompassed follow-up modified Rankin Scale (mRS) scores, imaging asses

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.